-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences study links DecisionDx-Melanoma i31-SLNB low-risk result to 3% sentinel node positivity and 98% three-year recurrence-free survival

Reuters·03/13/2026 15:02:32

Please log in to view news